



OPEN ACCESS

EDITED AND REVIEWED BY

Paola Patrignani,
University of Studies G. d'Annunzio Chieti
and Pescara, Italy

*CORRESPONDENCE

Wilbert Bouwman,
✉ Wilbert.bouwman@philips.com

SPECIALTY SECTION

This article was submitted to
Inflammation Pharmacology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 10 March 2023

ACCEPTED 28 March 2023

PUBLISHED 05 April 2023

CITATION

Bouwman W, Verhaegh W and
van de Stolpe A (2023), Corrigendum:
Improved diagnosis of inflammatory
bowel disease and prediction and
monitoring of response to anti-TNF alpha
treatment based on measurement of
signal transduction pathway activity.
Front. Pharmacol. 14:1183639.
doi: 10.3389/fphar.2023.1183639

COPYRIGHT

© 2023 Bouwman, Verhaegh and van de
Stolpe. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original author(s)
and the copyright owner(s) are credited
and that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Improved diagnosis of inflammatory bowel disease and prediction and monitoring of response to anti-TNF alpha treatment based on measurement of signal transduction pathway activity

Wilbert Bouwman*, Wim Verhaegh and Anja van de Stolpe

Philips Research, Eindhoven, Netherlands

KEYWORDS

ulcerative colitis, crohn's disease, IBD, signal transduction pathway, treatment response

A Corrigendum on

[Improved diagnosis of inflammatory bowel disease and prediction and monitoring of response to anti-TNF alpha treatment based on measurement of signal transduction pathway activity](#)

by Bouwman W, Verhaegh W and van de Stolpe A (2022). *Front. Pharmacol.* 13:1008976. doi: 10.3389/fphar.2022.1008976

In the published article, there was an error in [Figure 2](#) as published. In this figure for the prediction and assessment of response to anti-TNF α remission-induction treatment in CD (A) a different TGFbeta pathway model version was used. The corrected [Figure 2](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

